Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice

Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results

(2016) Celia Oldenbuettel et al.   ANTIVIRAL THERAPY

Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients

(2016) Lisa K Naeger et al.   ANTIVIRAL THERAPY

Dolutegravir Monotherapy in HIV-Infected Naive Patients With

(2016) Massimiliano Lanzafame et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression

(2016) Jhon Rojas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia

(2016) C. Katlama et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: Table 1.

(2016) Casper Rokx et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

(2016) Jean-Guy Baril et al.   PLoS One

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

(2015) Camelia Gubavu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

(2014) Maureen Oliveira et al.   AIDS

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

(2013) François Raffi et al.   LANCET INFECTIOUS DISEASES

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

Humanized Mice Recapitulate Key Features of HIV-1 Infection: A Novel Concept Using Long-Acting Anti-Retroviral Drugs for Treating HIV-1

(2012) Marc Nischang et al.   PLoS One

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

(2011) Kendra E. Hightower et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure

(2009) S. Fransen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY